However, this finding was not influenced by PIK3CA mutational status, strengthening the assumption that the effect of AKT inhibitors does not mirror PI3K/AKT hyperactivation in HR-positive BC (Hrebien et al., 2019). The gene discussed is AKT1; the disease is breast cancer.